Kalaris Therapeutics CFO Resigns; Chief Accounting Officer Assumes Principal Financial Officer Role

summarizeSummary

Kalaris Therapeutics announced the resignation of its Chief Financial Officer, Matthew Gall, effective April 14, 2026, with Chief Accounting Officer Brett Hagen stepping in as Principal Financial Officer.

check_boxKey Events

• Chief Financial Officer Resigns

  Matthew Gall notified Kalaris Therapeutics, Inc. of his decision to resign as Chief Financial Officer, effective April 14, 2026.

• Chief Accounting Officer Appointed Principal Financial Officer

  Brett Hagen, the Company's Chief Accounting Officer and principal accounting officer, will also serve as the principal financial officer, effective April 14, 2026.

auto_awesomeAnalysis

The departure of a Chief Financial Officer is a significant executive change that can raise questions about leadership stability and financial strategy. This event occurs shortly after Kalaris Therapeutics filed universal shelf and resale registration statements, signaling potential future capital raises. While the internal appointment of the Chief Accounting Officer as Principal Financial Officer provides immediate continuity, investors may scrutinize the reasons behind the CFO's resignation and its potential impact on the company's financial operations and ongoing capital raising efforts.